Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a strong financial position and optimistic guidance, which are positive factors. However, there are concerns about high R&D expenses, projected net losses, and ongoing litigation with Lilly. The Q&A reveals management's active engagement in partnerships and confidence in product development, but also highlights uncertainties in litigation and lack of specific benchmarks for remittive effects. These mixed signals suggest a neutral impact on stock price, especially given the absence of a market cap for further context.
Key Financial Performance
Cash and Investments $175.9 million at the end of Q2 2025, with no debt on the balance sheet. This was strengthened by a secondary public offering on July 2, 2025, resulting in $107.5 million in net proceeds. The cash runway is extended into Q1 2027.
Noncash Royalty Revenue $11.2 million for Q2 2025, with an expectation of $40 million for the full year.
R&D Expense $29.9 million for Q2 2025, with full-year guidance between $125 million and $130 million. This includes $5 million to $10 million of noncash depreciation and stock-based compensation expense.
G&A Expense $17.1 million for Q2 2025, with full-year guidance between $70 million and $75 million. This includes $5 million to $10 million of noncash depreciation and stock-based compensation expense.
Noncash Interest Expense $5.4 million for Q2 2025, expected to total $20 million for the full year.
Noncash Loss from Equity Method Investment $2.4 million for Q2 2025, with an expectation of $10 million for the full year.
Net Loss $41.6 million for Q2 2025, or $2.95 basic and diluted net loss per share. Excluding noncash loss from equity method investment, the non-GAAP net loss was $39.2 million or $2.78 basic and diluted net loss per share.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rezpegaldesleukin (REZPEG): Reported compelling initial data in atopic dermatitis, establishing it as a potential first-in-class novel T regulatory mechanism. Phase IIb study for moderate to severe atopic dermatitis showed statistical significance in multiple efficacy endpoints. FDA Fast Track designation granted for atopic dermatitis and alopecia areata. Phase III readiness activities underway, with plans to start in 2026.
Alopecia Areata Treatment: Phase IIb study results expected in December 2025. Targeting a market projected to grow to $2 billion by 2033. Positioned as a novel mechanism addressing underlying pathology of hair loss.
Type 1 Diabetes: TrialNet-sponsored Phase II clinical trial to begin by the end of 2025, targeting new onset type 1 diabetes.
TNFR2 Agonist Antibody Program: Progressing through IND-enabling studies, aiming for clinical advancement in 2026. Focused on potentiating Treg function and maintenance.
Atopic Dermatitis Market: Market has grown to $15 billion in U.S. sales and is expected to reach $30 billion by 2033. REZPEG aims to capture a significant share by addressing unmet needs and offering a differentiated mechanism.
Alopecia Areata Market: Projected to grow to $2 billion by 2033. REZPEG positioned to take a significant share due to its novel mechanism.
Financial Position: Completed $115 million equity financing in June 2025, extending cash runway into 2027. Ended Q2 2025 with $175.9 million in cash and investments.
R&D and G&A Expenses: R&D expense for Q2 2025 was $29.9 million, with full-year guidance of $125-$130 million. G&A expense for Q2 2025 was $17.1 million, with full-year guidance of $70-$75 million.
Regulatory Strategy: FDA Fast Track designation for REZPEG in atopic dermatitis and alopecia areata. Phase III readiness activities and clinical trial design planning underway for REZPEG.
Pipeline Expansion: Advancing multiple programs, including REZPEG for type 1 diabetes and TNFR2 agonist antibody program, to diversify therapeutic offerings.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Development Risks: The company faces uncertainties and risks related to the development and regulatory approval of its drug candidates, including rezpegaldesleukin (REZPEG). The success of Phase III trials and alignment with the FDA are critical for future progress.
Market Competition: The atopic dermatitis market is dominated by IL-13-based therapies, which have established a strong presence. Competing against these therapies, despite their side effects, poses a significant challenge for REZPEG.
Financial Sustainability: Although the company has extended its cash runway into 2027, it remains dependent on successful fundraising and the commercial success of its drug candidates to sustain operations.
Clinical Trial Risks: The outcomes of ongoing and future clinical trials, including those for atopic dermatitis, alopecia areata, and type 1 diabetes, are uncertain and could impact the company's strategic plans.
Supply Chain and Manufacturing: Securing additional manufacturing for REZPEG and ensuring readiness for Phase III trials are critical tasks that could face logistical or operational challenges.
Dependence on Single Mechanism: The company’s focus on T regulatory cell science and the IL-2 pathway for multiple indications increases its exposure to risks if this mechanism fails to deliver expected results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Development Plans for REZPEG: Nektar plans to initiate Phase III development for REZPEG in 2026, targeting both biologic-naive and biologic-experienced patients with atopic dermatitis. The company is preparing for an end of Phase II meeting with the FDA later this year to finalize trial designs.
Market Opportunity for REZPEG: The atopic dermatitis market is projected to grow from $15 billion in U.S. sales to nearly $30 billion by 2033. Nektar aims to position REZPEG as a differentiated therapy with a fast onset of action and fewer side effects compared to IL-13-based therapies.
Upcoming Data Releases: Additional data from the REZOLVE-AD study will be available in Q1 2026, including durability and depth of response for REZPEG out to week 52. Data from the Phase IIb study in alopecia areata is expected in December 2025.
Alopecia Areata Market Potential: The alopecia areata treatment market is projected to grow to $2 billion by 2033. Nektar believes REZPEG could capture a significant share due to its novel mechanism and potential efficacy.
Financial Guidance: Nektar expects to end 2025 with $180-$185 million in cash and investments, extending its cash runway into 2027. The company plans to allocate resources to Phase III readiness activities for REZPEG and development of other pipeline candidates.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you started to engage with regulators with the 16-week data?
A:Yes, the engagement with regulators is ongoing. The plan is to hold an end of Phase II meeting before the end of the year. The trial design will include two monotherapy studies that are identical in design, a long-term extension study for safety data, and additional studies required for BLA submission. The trials will include both biologic-naive and biologic-experienced patients to achieve a broad label for REZPEG.
Q:What are your thoughts on partnership opportunities for REZPEG in AD?
A:The company is actively talking to partners, including strategics and financing partners, for potential collaboration on REZPEG. There are options for nondilutive financial methods, such as monetizing their 3%-4% stake in dapimab. The company is prepared to put REZPEG into Phase III in 2026 and has a financial runway into 2027.
Q:What is your thought process around a competitor product profile for alopecia areata?
A:There are no approved biologics for alopecia areata, and JAK inhibitors require continuous dosing with safety liabilities. The study's primary endpoint is based on percent change from baseline in SALT scores, with benchmarks set by JAK inhibitors. The goal is to achieve or exceed these benchmarks and potentially be the first biologic in this space.
Q:What underpins your confidence that REZPEG will be active in biologic-experienced atopic dermatitis patients?
A:The mechanism of REZPEG does not overlap or conflict with post-IL-13 biology. It has the potential to block multiple kinds of polarized T cell inflammation and is a cellular agonist, which gives confidence in its activity for both biologic-naive and biologic-experienced patients.
Q:What are your thoughts on the biological therapy trial design for biologic-experienced patient cohorts in AD?
A:The first Phase III study will focus on IL-4 and IL-13 class mechanisms, including DUPIXENT, lebrikizumab, and others. The goal is to include a broad range of biologic-experienced patients, even as new mechanisms like OX40 become available.
Q:What is your expectation for the induction efficacy primary endpoint duration of therapy in Phase III?
A:The Phase III program will include 52-week studies with a focus on both induction and maintenance regimens. The company plans to assess remittive potential through randomized withdrawal components in long-term extensions.
Q:Does the read-through from atopic dermatitis data apply to the alopecia trial?
A:Yes, the atopic dermatitis data provides a positive read-through to the alopecia trial. The company is optimistic about achieving meaningful outcomes in alopecia areata, leveraging the mechanism's potential to be the first biologic in this space.
Q:Are there any updates on the Lilly litigation?
A:The company is committed to pursuing the lawsuit against Lilly, believing they were significantly injured, including delays in the marketplace. The REZPEG data strengthens their position in the litigation.
Q:What updates are there on studies to understand and mitigate injection site reactions (ISRs)?
A:Studies using primary skin organoid cultures have identified IL-2 as the cause of ISRs. The company plans to launch with a prefilled syringe in an auto-injector to standardize administration and reduce ISRs. ISRs were mostly mild to moderate and self-resolving, with minimal impact on patient adherence.
Q:What data points or efficacy bar could suggest a remittive effect for REZPEG in atopic dermatitis?
A:The upcoming maintenance data in early next year will still be on-treatment data, focusing on deepening responses and durability. The Phase IIb study includes a 52-week off-drug follow-up to assess remission, with early Phase I data suggesting potential remittive effects.
Q:What is your comfort level with the powering of the maintenance phase of the REZPEG trial after dropouts in the induction portion?
A:The company feels good about the powering of the maintenance phase, with 190 people moving into this phase, aligning with their modeling. The maintenance phase includes a 1:1 randomization for once-a-month or once-every-three-month regimens.
Q:Why is OX40 considered a benchmark for REZPEG in atopic dermatitis?
A:The OX40 Phase IIb studies have similar study designs, patient populations, and statistical methods to REZPEG's studies. OX40 is also a novel mechanism relative to IL-13s, making it a relevant comparison.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the Lilly litigation, citing legal constraints, and did not offer clear benchmarks for what would constitute a remittive effect in atopic dermatitis. Additionally, while they discussed potential mitigation strategies for ISRs, they did not provide detailed timelines or specific outcomes for these efforts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cha
Co Research
FDA
II meeting
III readiness
III study
IIb study
Inc Research
LLC Research
Phase II
Phase III
Phase IIb
REZOLVE AD
REZPEG share
REZPEG week
Research Division
TNFR
agent
approach access
arm week
assessment
cell hair
class novel
conjunctivitis
crossover
cut response
effector cell
imbalance effector
kilogram week
landscape
market
microgram kilogram
patient dermatitis
patient week
reduction
significance
NKTR Transcript
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reveals a negative sentiment due to a 20% decline in revenue and increased net loss, coupled with higher R&D expenses. The lack of strategic initiatives and shareholder return discussion further dampens the outlook. Despite potential in Rezpegaldesleukin, the absence of concrete advancements or partnerships, combined with the risks in forward-looking statements, contributes to a negative sentiment. The cash position decrease also raises concerns about financial health, leading to a likely negative stock price movement.
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture. The financial performance shows a decrease in revenue but an improved net loss and positive cash flow, leading to a neutral sentiment. The development plans for Rezpegaldesleukin and future data presentations are positive, but the lack of discussion on shareholder returns and inherent risks in forward-looking statements balance this out. The Q&A section did not provide additional insights to shift the sentiment significantly. Overall, the stock price is likely to remain stable over the next two weeks.
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Positive11-7
Despite some unclear management responses, the earnings call highlights strong market opportunities for REZPEG, particularly in atopic dermatitis and alopecia areata. The company's financial guidance shows a healthy cash runway, and the potential differentiation of REZPEG from competitors is promising. The Q&A section reveals significant interest in REZPEG's unique mechanism and its potential safety advantages over JAK inhibitors. Overall, these factors suggest a positive sentiment towards Nektar's future prospects, supporting a positive stock price movement prediction.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary indicates a strong financial position and optimistic guidance, which are positive factors. However, there are concerns about high R&D expenses, projected net losses, and ongoing litigation with Lilly. The Q&A reveals management's active engagement in partnerships and confidence in product development, but also highlights uncertainties in litigation and lack of specific benchmarks for remittive effects. These mixed signals suggest a neutral impact on stock price, especially given the absence of a market cap for further context.
NKTR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
